Developer docs
API playgroundTry for free, no card

Search company profiles

HLS Therapeutics

Full company profile

uuid0003r2e

Namestring
HLS Therapeutics
Legal namestring
HLS Therapeutics Inc.
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEtobicoke, Canada
HQ citystring
Etobicoke
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, cardiovascular therapies, treatment-resistant schizophrenia, LDL-cholesterol therapy, branded pharmaceutical commercialization
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Offices of Mental Health Practitioners (except Physicians)621330
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

HLS generates revenue through the sale of branded pharmaceutical products including CLOZARIL (clozapine) for treatment-resistant schizophrenia and VASCEPA (icosapent ethyl) for cardiovascular risk reduction. Product sales are generated from both Canadian and U.S. markets.

biospace.com
2Royalties
TypeLicensing Royalties
Description

The company receives royalty revenue from its royalty portfolio, which includes multiple indications and is marketed by third parties. Royalty revenue was $0.25 million in Q1 2026.

hlstherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1VASCEPA
Description

Cardiovascular risk reduction product (icosapent ethyl) marketed in Canada

hlstherapeutics.com
+4 more records
Core offering1 text field

HLS Therapeutics acquires, in-licenses, and commercializes branded pharmaceutical products across North America, focused on two therapeutic areas: psychiatric disorders led by CLOZARIL (clozapine) for treatment-resistant schizophrenia, and cardiovascular disease anchored by VASCEPA (icosapent ethyl) for cardiovascular risk reduction and the newly launched NILEMDO (bempedoic acid) for LDL-cholesterol reduction. The company supports these therapies with the CSAN Pronto point-of-care diagnostic for CLOZARIL patient monitoring and the MyCare Psychiatry therapeutic drug monitoring service, distributing through specialty pharmacy programs and payer/reimbursement channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Vascepa net sales increased 15% to $4.8 million in Q1 2026, with 18% unit growth reflecting sustained demand
+4 more records
Product overview1 text field

HLS Therapeutics is a pharmaceutical company focused on the acquisition and commercialization of branded medicines in North America. The company's product portfolio centers on two therapeutic areas: psychiatric disorders (CLOZARIL for treatment-resistant schizophrenia, supported by CSAN Pronto diagnostics and MyCare Psychiatry monitoring services) and cardiovascular disease (VASCEPA for CV risk reduction, and the newly launched NILEMDO and upcoming NEXLIZET for LDL-cholesterol reduction). The company also holds a royalty portfolio of products marketed by third parties globally. The core portfolio strategy involves in-licensing or acquiring late-stage and commercial-stage pharmaceutical products, ensuring regulatory compliance with FDA and Health Canada, and providing reliable market access.

Product and service5 records
1CLOZARIL (clozapine)
CategoryBranded pharmaceutical (psychiatric)
Description

Treatment-resistant schizophrenia medication marketed in both the United States and Canada. Requires blood monitoring through the CSAN Pronto system.

2VASCEPA (icosapent ethyl)
CategoryBranded pharmaceutical (cardiovascular)
Description

Cardiovascular risk reduction therapy marketed in Canada. EPA-based treatment for cardiovascular and cardiometabolic conditions.

3NILEMDO (bempedoic acid)
CategoryBranded pharmaceutical (cardiovascular)
Description

First-in-class, once-daily oral non-statin therapy for reducing LDL-cholesterol in patients at risk of cardiovascular disease who cannot reach LDL-C goals on statin therapy or who are statin intolerant.

4NEXLIZET (bempedoic acid/ezetimibe)
CategoryBranded pharmaceutical (cardiovascular)
Description

Bempedoic acid and ezetimibe combination therapy for cardiovascular risk reduction, in-licensed from Esperion Therapeutics with Canadian commercial launch expected in 2027.

5CSAN Pronto
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-14
Description

HLS Therapeutics and Amarin collaborated to present scientific data on VASCEPA and EPA (eicosapentaenoic acid) at the Canadian Cardiovascular Congress in October 2025. The collaboration focused on clinical and mechanistic benefits of icosapent ethyl (IPE) for cardiovascular and cardiometabolic conditions, emphasizing ongoing research and the commercial availability of VASCEPA in Canada.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

HLS Therapeutics in-licensed exclusive Canadian rights to NILEMDO (bempedoic acid) and NEXLIZET from Esperion Therapeutics in May 2025. NILEMDO received Health Canada approval in November 2025 and was commercially launched in Canada in March 2026. This partnership significantly expands HLS's cardiovascular portfolio and represents a potential franchise that could more than double company revenue.

Strategic tierMinorTypeOthers
Description

HLS Therapeutics supports Medications Return Programs managed by the Health Products Stewardship Association (HPSA), which provide safe and convenient disposal of unused or expired medications in an environmentally responsible manner.

Strategic tierMinorTypeOthers
Description

Partnership with Health Stewards organization to support medication return programs and proper disposal of pharmaceutical products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical company with a defined CNS franchise (Xywav, Epidiolex, Sunosi) that follows a similar branded/specialty pharma growth model, commercializing differentiated CNS products in North America with established sales infrastructure.

TypeDirect peer
Description

Cardiovascular-focused specialty pharma behind VASCEPA (icosapent ethyl), the same molecule HLS commercializes in Canada; HLS partners directly with Amarin on Canadian cardiovascular launches and scientific exchange programs.

TypeOthers
Description

Specialty pharma where HLS's CEO Craig Millian and CCO Brian Walsh previously held senior leadership roles (COO and VP Corp Dev/Commercial respectively); provides talent/operating-model comparability rather than direct product overlap.

TypeDirect peer
Description

Specialty CNS pharma company selling branded neurology/psychiatry products (e.g., Trokendi XR, Oxtellar XR) through a focused field force, closely matching HLS's branded-pharma-stewardship model in psychiatry/neurology.

5Endo International
TypeBroad incumbent
Description

Specialty pharmaceutical company with branded and generic CNS, CV and pain products; a broad incumbent whose branded specialty portfolio includes therapeutic areas adjacent to HLS's CNS and CV focus.

6H. Lundbeck
TypeDirect peer
Description

Global specialty pharmaceutical company focused on brain diseases (psychiatry and neurology) including branded CNS products, serving a similar prescriber base of psychiatrists and neurologists with branded specialty therapeutics.

TypeBroad incumbent
Description

Large diversified specialty pharma with branded CNS, CV, and other specialty product portfolios; offers a much broader incumbent footprint but overlaps with HLS on branded specialty strategy and post-exclusivity lifecycle management.

TypeDirect peer
Description

Originator of NILEMDO (bempedoic acid) and NEXLIZET, whose exclusive Canadian rights were in-licensed to HLS in May 2025; comparable specialty CV pharma commercializing the same franchise in different geographies.

TypeEmerging player
Description

Emerging CNS specialty pharma behind Caplyta (lumateperone), focused on psychiatry indications including treatment-resistant populations; overlaps with HLS's CNS specialty commercial model.

TypeBroad incumbent
Description

Long-standing specialty CNS pharmaceutical company marketing branded central nervous system therapies; comparable prescriber targets and lifecycle brand approach to HLS's CLOZARIL and MyCare Psychiatry offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

HLS Therapeutics

Specialty Pharmaceuticalshlstherapeutics.com

HLS Therapeutics firmographics

Firmographics
Name
HLS Therapeutics
Legal name
HLS Therapeutics Inc.
Website
https://hlstherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

HLS Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Offices of Mental Health Practitioners (except Physicians) (621330)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Cardiovascular therapies
  • Treatment-resistant schizophrenia
  • LDL-cholesterol therapy
  • Branded pharmaceutical commercialization

Where HLS Therapeutics is headquartered

Location

Headquarters

HQ city
Etobicoke
HQ country
Canada
HQ region
North America

Offices5 records

Markets served

HLS Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: HLS generates revenue through the sale of branded pharmaceutical products including CLOZARIL (clozapine) for treatment-resistant schizophrenia and VASCEPA (icosapent ethyl) for cardiovascular risk reduction. Product sales are generated from both Canadian and U.S. markets.
  2. Royalties: The company receives royalty revenue from its royalty portfolio, which includes multiple indications and is marketed by third parties. Royalty revenue was $0.25 million in Q1 2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

HLS Therapeutics product offering

Product offering

Core offering

HLS Therapeutics acquires, in-licenses, and commercializes branded pharmaceutical products across North America, focused on two therapeutic areas: psychiatric disorders led by CLOZARIL (clozapine) for treatment-resistant schizophrenia, and cardiovascular disease anchored by VASCEPA (icosapent ethyl) for cardiovascular risk reduction and the newly launched NILEMDO (bempedoic acid) for LDL-cholesterol reduction. The company supports these therapies with the CSAN Pronto point-of-care diagnostic for CLOZARIL patient monitoring and the MyCare Psychiatry therapeutic drug monitoring service, distributing through specialty pharmacy programs and payer/reimbursement channels.

Product overview

HLS Therapeutics is a pharmaceutical company focused on the acquisition and commercialization of branded medicines in North America. The company's product portfolio centers on two therapeutic areas: psychiatric disorders (CLOZARIL for treatment-resistant schizophrenia, supported by CSAN Pronto diagnostics and MyCare Psychiatry monitoring services) and cardiovascular disease (VASCEPA for CV risk reduction, and the newly launched NILEMDO and upcoming NEXLIZET for LDL-cholesterol reduction). The company also holds a royalty portfolio of products marketed by third parties globally. The core portfolio strategy involves in-licensing or acquiring late-stage and commercial-stage pharmaceutical products, ensuring regulatory compliance with FDA and Health Canada, and providing reliable market access.

Differentiator

Problem solved

Functional benefit

Brands

  • VASCEPA: Cardiovascular risk reduction product (icosapent ethyl) marketed in Canada
  • NILEMDO
  • CLOZARIL
  • CSAN Pronto
  • MyCare Psychiatry

Products and services

  • CLOZARIL (clozapine) Treatment-resistant schizophrenia medication marketed in both the United States and Canada. Requires blood monitoring through the CSAN Pronto system.
  • VASCEPA (icosapent ethyl) Cardiovascular risk reduction therapy marketed in Canada. EPA-based treatment for cardiovascular and cardiometabolic conditions.
  • NILEMDO (bempedoic acid) First-in-class, once-daily oral non-statin therapy for reducing LDL-cholesterol in patients at risk of cardiovascular disease who cannot reach LDL-C goals on statin therapy or who are statin intolerant.
  • NEXLIZET (bempedoic acid/ezetimibe) Bempedoic acid and ezetimibe combination therapy for cardiovascular risk reduction, in-licensed from Esperion Therapeutics with Canadian commercial launch expected in 2027.
  • CSAN Pronto

Quantifiable outcome

  • Vascepa net sales increased 15% to $4.8 million in Q1 2026, with 18% unit growth reflecting sustained demand
  • +4 more outcomes

Companies that use HLS Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

HLS Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

HLS Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • AmarinminorStrategic or Co-development Partner · 14 October 2025HLS Therapeutics and Amarin collaborated to present scientific data on VASCEPA and EPA (eicosapentaenoic acid) at the Canadian Cardiovascular Congress in October 2025. The collaboration focused on clinical and mechanistic benefits of icosapent ethyl (IPE) for cardiovascular and cardiometabolic conditions, emphasizing ongoing research and the commercial availability of VASCEPA in Canada.
  • Esperion TherapeuticscoreStrategic or Co-development Partner · 1 May 2025HLS Therapeutics in-licensed exclusive Canadian rights to NILEMDO (bempedoic acid) and NEXLIZET from Esperion Therapeutics in May 2025. NILEMDO received Health Canada approval in November 2025 and was commercially launched in Canada in March 2026. This partnership significantly expands HLS's cardiovascular portfolio and represents a potential franchise that could more than double company revenue.
  • Health Products Stewardship Association (HPSA)minorOthersHLS Therapeutics supports Medications Return Programs managed by the Health Products Stewardship Association (HPSA), which provide safe and convenient disposal of unused or expired medications in an environmentally responsible manner.
  • Health StewardsminorOthersPartnership with Health Stewards organization to support medication return programs and proper disposal of pharmaceutical products.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

HLS Therapeutics competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Specialty pharmaceutical company with a defined CNS franchise (Xywav, Epidiolex, Sunosi) that follows a similar branded/specialty pharma growth model, commercializing differentiated CNS products in North America with established sales infrastructure.
  • Amarin Corporation: Cardiovascular-focused specialty pharma behind VASCEPA (icosapent ethyl), the same molecule HLS commercializes in Canada; HLS partners directly with Amarin on Canadian cardiovascular launches and scientific exchange programs.
  • Supernus Pharmaceuticals: Specialty CNS pharma company selling branded neurology/psychiatry products (e.g., Trokendi XR, Oxtellar XR) through a focused field force, closely matching HLS's branded-pharma-stewardship model in psychiatry/neurology.
  • H. Lundbeck: Global specialty pharmaceutical company focused on brain diseases (psychiatry and neurology) including branded CNS products, serving a similar prescriber base of psychiatrists and neurologists with branded specialty therapeutics.
  • Esperion Therapeutics: Originator of NILEMDO (bempedoic acid) and NEXLIZET, whose exclusive Canadian rights were in-licensed to HLS in May 2025; comparable specialty CV pharma commercializing the same franchise in different geographies.

Others

  • Corbus Pharmaceuticals: Specialty pharma where HLS's CEO Craig Millian and CCO Brian Walsh previously held senior leadership roles (COO and VP Corp Dev/Commercial respectively); provides talent/operating-model comparability rather than direct product overlap.

Broad incumbents

  • Endo International: Specialty pharmaceutical company with branded and generic CNS, CV and pain products; a broad incumbent whose branded specialty portfolio includes therapeutic areas adjacent to HLS's CNS and CV focus.
  • Bausch Health: Large diversified specialty pharma with branded CNS, CV, and other specialty product portfolios; offers a much broader incumbent footprint but overlaps with HLS on branded specialty strategy and post-exclusivity lifecycle management.
  • Purdue Pharma: Long-standing specialty CNS pharmaceutical company marketing branded central nervous system therapies; comparable prescriber targets and lifecycle brand approach to HLS's CLOZARIL and MyCare Psychiatry offerings.

Emerging players

  • Intra-Cellular Therapies: Emerging CNS specialty pharma behind Caplyta (lumateperone), focused on psychiatry indications including treatment-resistant populations; overlaps with HLS's CNS specialty commercial model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

HLS Therapeutics social profiles

Digital presence

HLS Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

HLS Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

HLS Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

HLS Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

HLS Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HLS Therapeutics

What does HLS Therapeutics do?

HLS Therapeutics acquires, in-licenses, and commercializes branded pharmaceutical products across North America, focused on two therapeutic areas: psychiatric disorders led by CLOZARIL (clozapine) for treatment-resistant schizophrenia, and cardiovascular disease anchored by VASCEPA (icosapent ethyl) for cardiovascular risk reduction and the newly launched NILEMDO (bempedoic acid) for LDL-cholesterol reduction. The company supports these therapies with the CSAN Pronto point-of-care diagnostic for CLOZARIL patient monitoring and the MyCare Psychiatry therapeutic drug monitoring service, distributing through specialty pharmacy programs and payer/reimbursement channels.

Is HLS Therapeutics a public or private company?

HLS Therapeutics is a public company. It is classified as public and is currently operating.

When was HLS Therapeutics founded?

HLS Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is HLS Therapeutics based?

HLS Therapeutics is headquartered in Etobicoke, Canada, in the North America region.

How does HLS Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are royalties.

Who are HLS Therapeutics's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Amarin Corporation, Supernus Pharmaceuticals, H. Lundbeck and Esperion Therapeutics. Corbus Pharmaceuticals is listed as an others. Broad incumbents are Endo International, Bausch Health and Purdue Pharma. Intra-Cellular Therapies is listed as an emerging player.

Does HLS Therapeutics have an API?

No public API is recorded for HLS Therapeutics.

What industry is HLS Therapeutics in?

HLS Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 621330 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaHLS Therapeutics Inc. 2026 Q3 - Results - Earnings Call PresentationHLS Therapeutics reported Q3 2026 EPS of -$0.10, beating by $0.01, and revenue of $20.18M, missing by $1.16M. The company's market cap is $114.16M, with revenue growth of 1.86% year-over-year.Business & FinancialHLS Therapeutics Inc.HLS Therapeutics reported Q3 2026 revenue of $14.2 million, adjusted EBITDA of $5.0 million, and cash from operations of $1.8 million. These figures represent decreases from the prior quarter's $13.5 million, $4.9 million, and $2.5 million, respectively. The company's shares traded unchanged at $4.19.Business & FinancialHLS Therapeutics Inc.HLS Therapeutics announced an agreement with Bayer to commercialize VERQUVO (vericiguat) in Canada. The company's shares rose $0.03 to $4.50. No further details were disclosed.MarketBeatHLS Therapeutics Targets 2027 Growth With Cardiovascular Expansion and New DealsHLS Therapeutics plans to drive growth from 2027, focusing on its cardiovascular portfolio and new deals. The company reduced net debt by 57% and raised adjusted EBITDA to about $15 million, with Vascepa and new products NILEMDO and NEXLIZET as key drivers. It expects a Health Canada decision on NEXLIZET by year-end, potentially launching in 2027.Markets DailyHLS Therapeutics Inc. (OTCMKTS:HLTRF) Sees Significant Decline in Short InterestHLS Therapeutics saw short interest fall 93.5% to 100 shares as of September 30th, from 1,546 shares on September 15th. Raymond James raised its rating to Strong Buy, and the stock traded flat at $2.75.BioSpaceHLS Therapeutics Announces Board of Directors ChangesHLS Therapeutics appointed Linda Maxwell and Mark DeLong as independent directors, effective today, following departures of Dr. Kyle Dempsey and Christine Elliott. The board now has eight directors, six independent, with Maxwell joining the Audit Committee and DeLong the Compensation and Governance Committee.NewswireHLS Therapeutics Increases Normal Course Issuer BidHLS Therapeutics increased its normal course issuer bid from 1.5 million to 1.87 million common shares, about 10% of the public float. The bid runs until June 24, 2027, and purchases are made by Raymond James at market price. To date, the company has repurchased 1,054,037 shares at a weighted average price of $3.90.Markets DailyHLS Therapeutics (TSE:HLS) Sets New 12-Month Low – Here’s What HappenedHLS Therapeutics Inc. reached a new 52-week low on Wednesday, trading as low as C$3.71 and closing at C$3.75. Analysts have raised their ratings, with Raymond James Financial upgrading the stock from 'outperform' to 'strong-buy' with a target price increase to C$8.00. The company's financials indicate a challenging situation, with a negative net margin and expected earnings per share for the current fiscal year of -0.12.YahooHLS Therapeutics (TSX:HLS) Stock Fair Value Rises After Analysts Turn More PositiveHLS Therapeutics saw its stock fair value rise to C$7.36 following more positive analyst sentiment, with Raymond James upgrading the stock to Strong Buy and raising its price target to C$8. The valuation model updates reflect increased revenue growth assumptions of 13.73% and an improved net profit margin outlook of 7.88%. Canaccord also shifted its rating to Buy, though it maintained a more conservative C$5 price target.